Abstract: The invention comprises (1) anhydrous crystalline forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide, (2) pharmaceutical compositions comprising at least one such form, (3) methods for the treatment of a phosphodiesterase-5-mediated condition using at least one such form, and (4) methods for preparing such forms. The compound N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide has the following structure (I).

Abstract: The invention comprises (1) anhydrous crystalline forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide, (2) pharmaceutical compositions comprising at least one such form, (3) methods for the treatment of a phosphodiesterase-5-mediated condition using at least one such form, and (4) methods for preparing such forms. The compound N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide has the following structure (I).

Abstract: The invention comprises (1) anhydrous crystalline forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide, (2) pharmaceutical compositions comprising at least one such form, (3) methods for the treatment of a phosphodiesterase-5-mediated condition using at least one such form, and (4) methods for preparing such forms. The compound N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide has the following structure (I).

Abstract: The invention comprises (1) anhydrous crystalline forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide, (2) pharmaceutical compositions comprising at least one such form, (3) methods for the treatment of a phosphodiesterase-5-mediated condition using at least one such form, and (4) methods for preparing such forms. The compound N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide has the following structure (I).

Abstract: The invention comprises (1) anhydrous crystalline forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide, (2) pharmaceutical compositions comprising at least one such form, (3) methods for the treatment of a phosphodiesterase-5-mediated condition using at least one such form, and (4) methods for preparing such forms. The compound N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide has the following structure (I).

Abstract: A sample introduction system includes at least two, and preferably three, syringe pumps. The flow rates of two of the syringe pumps are varied, while keeping the overall flow rate constant. The sample introduction system is preferably utilised in an analytical instrument, such as to determine the concentration of an analyte in a sample.

Abstract: The invention comprises (1) anhydrous crystalline forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide, (2) pharmaceutical compositions comprising at least one such form, (3) methods for the treatment of a phosphodiesterase-5-mediated condition using at least one such form, and (4) methods for preparing such forms. The compound N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide has the following structure (I).

Abstract: A sample introduction system includes at least two, and preferably three, syringe pumps. The flow rates of two of the syringe pumps are varied, while keeping the overall flow rate constant. The sample introduction system is preferably utilized in an analytical instrument, such as to determine the concentration of an analyte in a sample.

Abstract: An Inductively Coupled Plasma (“ICP”) mass spectrometer is disclosed comprising a mass filter and a reaction/collision cell. Analyte ions and background ions having the same nominal mass to charge ratio are transmitted by the mass filter. The analyte ions selectively react with gas in the reaction/collision cell to form product ions having different mass to charge ratios. By measuring the intensity of the product ions the intensity of the analyte ions can be determined. According to less preferred embodiments background ions may be neutralised or reacted in the reaction/collision cell.

Abstract: A system that displays images and other data of products in the form of an electronic catalog and displayed on a monitor or other viewing device. The system is designed to receive input from a user thereof and is animated to simulate the page turns of a conventional physical catalog. The system also provides for the automatic creation and update of its content through the use of a database containing product data, and maintains the ability to correlate products contained in the catalog for purposes of displaying related products, as well as products associated with the preferences or viewing and browsing history of the user.

Abstract: A mass spectrometer is disclosed comprising an AC or RF ion guide having a plurality of plate electrodes and an upper plate electrode and a lower plate electrode. One or more channels are formed within the plate electrodes so that an ion guiding region is formed within the ion guide. The channels and hence the ion guiding region may be curved.

Abstract: An Inductively Coupled Plasma (“ICP”) mass spectrometer is disclosed comprising a mass filter and a reaction/collision cell. Analyte ions and background ions having the same nominal mass to charge ratio are transmitted by the mass filter. The analyte ions selectively react with gas in the reaction/collision cell to form product ions having different mass to charge ratios. By measuring the intensity of the product ions the intensity of the analyte ions can be determined. According to less preferred embodiments background ions may be neutralised or reacted in the reaction/collision cell.

Abstract: A mass spectrometer is disclosed comprising an AC or RF ion guide having a plurality of plate electrodes and an upper plate electrode and a lower plate electrode. One or more channels are formed within the plate electrodes so that an ion guiding region is formed within the ion guide. The channels and hence the ion guiding region may be curved.

Abstract: A sample introduction system includes at least two, and preferably three, syringe pumps. The flow rates of two of the syringe pumps are varied, while keeping the overall flow rate constant. The sample introduction system is preferably utilised in an analytical instrument, such as to determine the concentration of an analyte in a sample.

Abstract: A sample introduction system includes at least two, and preferably three, syringe pumps. The flow rates of two of the syringe pumps are varied, while keeping the overall flow rate constant. The sample introduction system is preferably utilised in an analytical instrument, such as to determine the concentration of an analyte in a sample.